V6627
Anti-Vascular Endothelial Growth Factor antibody produced in goat
IgG fraction of antiserum, lyophilized powder
Synonym(s):
Anti-VEGF
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
goat
Quality Level
conjugate
unconjugated
antibody form
IgG fraction of antiserum
antibody product type
primary antibodies
clone
polyclonal
form
lyophilized powder
species reactivity
human
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 5-15 μg/mL
neutralization: suitable
western blot: 1-2 μg/mL
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... VEGFA(7422)
Specificity
The antibody will neutralize the biological activity of recombinant human VEGF165 and recombinant human VEGF121. The antibody shows ~20% cross-reactivity with recombinant mouse VEGF and recombinant rat VEGF.
Immunogen
recombinant human VEGF.
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing carbohydrates.
Preparation Note
Purified using protein G.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ilnur I Salafutdinov et al.
Biomedicines, 11(7) (2023-07-29)
The biosafety of gene therapy remains a crucial issue for both the direct and cell-mediated delivery of recombinant cDNA encoding biologically active molecules for the pathogenetic correction of congenital or acquired disorders. The diversity of vector systems and cell carriers
Laijian Sui et al.
Frontiers in cell and developmental biology, 12, 1374269-1374269 (2024-08-05)
The present study aimed to investigate the involvement of aberrant BMP8A expression in TNBC and bone metastasis. Aberrant expression of BMP8A in breast cancer was first determined by analyzing The Cancer Genome Atlas breast cancer cohort (TCGA-BRCA) and an immunohistochemical
Markus Theurl et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 32(9), 4815-4823 (2018-06-20)
The pathogenesis of diabetic neuropathy remains enigmatic. Damage to the vasa nervorum may be responsible for this disorder. Recently, we showed that secretoneurin (SN) induces angiogenesis in hindlimb and myocardial ischemia. Moreover, beneficial effects were observed in wound healing. We
Jertta-Riina Sarkanen et al.
Frontiers in pharmacology, 1, 147-147 (2010-01-01)
The developed standardized human cell based in vitro angiogenesis assay was intra-laboratory pre-validated to verify that the method is reliable and relevant for routine testing of modulators of angiogenesis, e.g., pharmaceuticals and industrial chemicals. This assay is based on the
Henning Ulrich et al.
Frontiers in pharmacology, 9, 500-500 (2018-06-06)
Bone marrow metastasis occurs in approximately 350,000 patients that annually die in the U.S. alone. In view of the importance of tumor cell migration into the bone marrow, we have here investigated effects of various concentrations of stromal cell-derived factor-1
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service